This study is now closed to participants. The M22-128 study is evaluating a combination of epcoritamab and lenalidomide for older adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), aiming to improve treatment outcomes and response rates.

The Reflection study enrolled Veterans who opted to be screened with Galleri, a multi-cancer early detection blood test which can detect the presence of 50+ cancers at time of blood draw.